Core Points - Allergan Aesthetics is celebrating the 25th anniversary of SkinMedica® with a promotion for Allē Members, offering double points on purchases and a chance to win $5,000 [1][2] - SkinMedica® has established itself as a leader in the skincare industry since its founding in 1999, known for its science-backed formulations and innovative products [1][2] - The brand's co-founder, Dr. Kimberly Butterwick, emphasizes the importance of scientific innovation in skincare and expresses optimism for the future of SkinMedica® [2] Company Overview - Allergan Aesthetics, a subsidiary of AbbVie, develops and markets a range of aesthetic products, including injectables and skincare [4] - AbbVie focuses on delivering innovative medicines across various therapeutic areas, including aesthetics, and aims to address significant health challenges [5]

Core Points - AbbVie has launched the AbbVie Migraine Career Catalyst Award, a contest aimed at supporting the career aspirations of individuals living with migraine, with winners receiving up to $2,500 for career development [1][2][3] - The contest is a response to the significant impact of migraine on the workplace, with over 113 million workdays lost annually in the U.S. due to the condition [1][2] - Migraine is the second leading cause of disability globally, affecting nearly 40 million people in the U.S. alone, highlighting the need for support in both personal and professional realms [2][4] Company Initiatives - AbbVie is the only company offering three prescription treatments tailored to meet the diverse needs of migraine patients, demonstrating its commitment to addressing the challenges faced by this population [4] - The company aims to empower individuals living with migraine through education and partnerships, helping them navigate barriers to care and access effective treatments [4] - The contest encourages participants to share their experiences with migraine and career goals through essays, videos, or audio clips, fostering a supportive community [2][3] Contest Details - The submission period for the AbbVie Migraine Career Catalyst Award is open until September 3, 2024, with winners announced around November 15, 2024 [3] - The contest is open to legal residents of the U.S., D.C., and Puerto Rico, aged 18 or over, with no purchase necessary to enter [3] - Each prize has an approximate retail value of $2,500, aimed at assisting winners in their professional development [3]

Industry Overview - The biotech sector is rebounding after a challenging five years, with ongoing clinical trials and FDA approvals driving demand for life-changing drugs [1] - The industry is expected to maintain demand due to continuous product pipelines, approvals, and research [1] Company Summaries Novo Nordisk (NVO) - Novo Nordisk has seen a 35% increase in sales for its drug Wegovy, which reduces cardiovascular risks in obese individuals, with over 25,000 weekly users [2] - The company reported a 28% increase in net profit, reaching $25.4 billion in the first quarter, and raised its sales growth outlook to between 19% and 27% for the year [2] - NVO stock is up 37% year-to-date and has increased over 450% in the past five years, indicating strong momentum for future growth [3] Moderna (MRNA) - Moderna's stock is currently at $145, down from a high of $449 in 2021, but it has increased 45% year-to-date [4] - The company is testing a vaccine for avian flu and has 45 drugs in its pipeline, with many in final-stage trials, including a combination shot for flu and COVID-19 [4][5] - Revenue has declined to $167 million, with a projected full-year sales of $4 billion, but the company aims to return to sales growth next year and break even by 2026 [5] AbbVie (ABBV) - AbbVie stock is up 5% year-to-date and 18% over the past 12 months, currently trading at $162, and is considered undervalued [6] - The company has a diverse pipeline and recently partnered with Gilgamesh Pharmaceuticals to expand its psychiatric therapy offerings, capitalizing on the growing demand in this market [6] - AbbVie has over 90 compounds in its pipeline and has seen a 59% increase in sales for its drug Rinvoq, while maintaining a dividend yield of 3.82% [7]

Core Insights - High-yield dividend stocks are expected to benefit from potential interest rate cuts by the Federal Reserve due to signs of cooling in the U.S. labor market, economy, and core inflation [1] - AbbVie and Pfizer are highlighted as attractive high-yield dividend stocks with strong yields and favorable valuations [1] AbbVie - AbbVie offers a dividend yield of 3.87% and has increased its dividend by 10% annually over the past five years, outperforming the average 6% increase among top dividend growers [2] - The company's shares trade at under 15 times forward earnings, significantly lower than the S&P 500's nearly 21 times forward earnings [2] - AbbVie is managing the loss of market exclusivity for its key drug Humira effectively, with strong sales from newer immunology medications Skyrizi and Rinvoq, and positive performance from the neuroscience drug Vraylar [3] Pfizer - Pfizer has a dividend yield of 5.87% and is trading at less than 13 times future earnings, positioning it for long-term outperformance [4] - The company has faced revenue declines due to reduced sales of COVID-19 products and a lack of investor interest in its acquisitions [4] - Pfizer is shifting focus towards oncology, which is expected to provide strong pricing power and competitive advantages, making it a top pick for dividend investors [5]

Core Insights - AbbVie has initiated the CERVINO Phase 3 trial to evaluate the efficacy, safety, and tolerability of ABBV-383 in patients with relapsed/refractory multiple myeloma (r/r MM) who have received at least two prior lines of therapy [1][2][3] - ABBV-383 is a bispecific antibody T-cell engager targeting B-cell maturation antigen (BCMA) and CD3, designed for monthly dosing to improve treatment simplicity for patients and physicians [1][2][5] Study Details - The CERVINO study is a global, multicenter, randomized, open-label trial involving adult patients (≥18 years) with r/r MM, excluding those who have received prior BCMA-targeted therapy [3][4] - Patients will be randomized 1:1 to receive either ABBV-383 60mg every 4 weeks or standard available therapies, with treatment continuing until disease progression or other discontinuation criteria are met [3][4] Endpoints and Enrollment - The primary endpoints of the study are progression-free survival and overall response rate, with secondary endpoints including overall survival and rates of complete response [4] - Approximately 380 patients will be enrolled across 140 sites globally [4] About ABBV-383 - ABBV-383 features bivalent high-avidity BCMA-binding domains and a low-affinity CD3-binding domain to reduce cytokine release, potentially allowing for extended dosing intervals [5] - BCMA is highly expressed on malignant plasma cells in multiple myeloma, making it a critical target for therapy [5][6] AbbVie's Commitment to Oncology - AbbVie is focused on transforming standards of care for patients with difficult-to-treat cancers, advancing a pipeline of investigational therapies across various cancer types [6][7] - The company is evaluating over 20 investigational medicines targeting widespread and debilitating cancers, aiming to improve patient access to cancer treatments [7]

–   First indications of RINVOQ (upadacitinib) for pediatric patients two years of age and older1–   RINVOQ is now approved for eight indications across immune-mediated inflammatory diseases1 NORTH CHICAGO, Ill., June 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that RINVOQ® (upadacitinib) is indicated in the U.S. for the treatment of pediatric patients two years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) as well as psoriatic arthritis (PsA), provided they ...

Core Insights - Allergan Aesthetics has launched a new referral program called "Refer a Friend" within its Allē Loyalty Rewards Program, allowing members to earn rewards for referring new users [1][2][3] - The program incentivizes both the referrer and the new user, with new users receiving up to $50 off their first purchase and referrers earning $10 for each successful referral [3][4] - The Allē program currently serves over seven million members across 27,000 practices, making it a significant player in the aesthetics market [4] Company Overview - Allergan Aesthetics is a subsidiary of AbbVie, focusing on developing, manufacturing, and marketing a range of aesthetic products, including injectables and skin care [6][7] - The company aims to provide innovation, education, and exceptional service to its customers, emphasizing a personal touch in its offerings [6] Market Insights - The referral program is based on market research indicating that 92% of consumers trust referrals from friends and family more than other advertising forms, highlighting the importance of word-of-mouth in the aesthetics industry [2] - The Allē program is unique in the aesthetics market as it allows members to earn points on over 50 non-Allergan Aesthetics treatments and brands, enhancing its appeal to consumers [4]

AbbVie (ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of Skyrizi (risankizumab) in the EU to treat adults with moderately to severely active ulcerative colitis (UC).The eligible patient population includes UC patients who have had an inadequate response, lost response, or were intolerant to either conventional or biologic therapy. The recommended treatment regime with AbbVie’s Skyriz ...

NORTH CHICAGO, Ill., June 3, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, will present at 9:00 a.m. Central time.A liv ...

The financial media does its best to keep you informed about what’s happening in the market. However, this has the effect of giving significant attention to a handful of leaders or laggards. That creates an opportunity for investors who have the patience to look for must-own overlooked stocks.  Overlooked stocks are not necessarily underperforming the market. In some cases, these stocks simply are slow and steady at a time when investors want to find the newest and brightest shiny object.  However, not ever ...